Molecular profiling of osteosarcoma in children and adolescents from different age groups using a next-generation sequencing panel

Cancer Genet. 2021 Nov:258-259:85-92. doi: 10.1016/j.cancergen.2021.10.002. Epub 2021 Oct 5.

Abstract

Osteosarcoma (OS) is a malignant bone tumor, with a peak of incidence in the second decade of life and possibly associated with the presence of germline mutations. Besides, clinicians have pointed to a second, rarer group of patients that develops OS before 10 years old. Here we access, through next-generation sequencing (NGS) strategy, the genetic alterations present in OS and blood samples from patients diagnosed before and during the second decade of life. A custom NGS panel, designed for the main alterations described in childhood and adolescence neoplasms, named Oncomine Childhood Cancer Research Assay (OCCRA©), was used. Of all 84 OS samples investigated, 42 (50%) presented some somatic variant, with TP53, MYC, CDK4, RB1 and PDGFRA genes harboring the most observed genetic variants. MYC CNVs were more frequent in tumors from patients diagnosed before 10 years old (X21= 5.18, p = 0.023). Additionally, patients diagnosed during the second decade of life presented a higher percentage of somatic and germline variants. Germline variants in TP53 and RB1 were found in 5 of the 11 (45.5%) patients analyzed. Clinical variables and tumor histopathological characteristics were also collected and correlated with our molecular findings.

Keywords: Cancer genetics; Cancer predisposition syndromes; Childhood cancer; Next-generation sequencing; OCCRA© panel; Osteosarcoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Biomarkers, Tumor / genetics*
  • Bone Neoplasms / genetics
  • Bone Neoplasms / pathology*
  • Child
  • DNA Copy Number Variations*
  • Female
  • Follow-Up Studies
  • Genetic Predisposition to Disease*
  • High-Throughput Nucleotide Sequencing / methods*
  • Humans
  • Male
  • Mutation*
  • Osteosarcoma / genetics
  • Osteosarcoma / pathology*
  • Prognosis

Substances

  • Biomarkers, Tumor